Under 21 CFR 101.93(g), making a disease claim on a dietary supplement label doesn't just violate labeling rules — it converts your product into an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. That means your supplement is legally subject to drug approval requirements, and marketing it without that approval is a federal violation.
This isn't an obscure technicality. FDA warning letters to supplement brands cite disease claims more frequently than almost any other violation. And the majority of those letters go to brands that didn't think they were making disease claims.
The FDA's Definition of "Disease"
Under 21 CFR 101.93(g)(1), a disease is defined as "damage to an organ, part, structure, or system of the body such that it does not function properly (e.g., cardiovascular disease), or a state of health leading to such dysfunctioning (e.g., hypertension)."
There is one important carve-out: diseases resulting from essential nutrient deficiencies — scurvy (vitamin C deficiency), pellagra (niacin deficiency), and similar classical deficiency diseases — are excluded from this definition. A supplement can legally say it helps prevent scurvy. It cannot legally say it helps prevent cardiovascular disease.
What triggers a disease claim finding
Under 21 CFR 101.93(g)(2), the FDA will find a disease claim if a statement claims, explicitly or implicitly, that the product:
Has an effect on a specific disease or class of diseases
Has an effect on the characteristic signs or symptoms of a disease — using lay or scientific terms
Has an effect on an abnormal condition that can cause significant or permanent harm
Has an effect on a disease through the product name, its formulation, a publication citation, or use of the term "disease" itself
Belongs to a class of products intended to treat disease
Augments a drug therapy for a disease
Has a role in the body's response to a disease or a vector of disease
The breadth of these criteria is significant. A claim doesn't need to say "treats" or "cures" to be a disease claim. Implied effects — through language, imagery, product naming, or context — are evaluated as rigorously as explicit ones.
The Implied Disease Claim Problem
Most brands that receive FDA warning letters for disease claims weren't making explicit claims. They were making implied ones — and they didn't realize it.
How implication works in FDA enforcement
Product names: A supplement called "HeartGuard" or "DiabetesShield" is, in context, making a disease claim through the product name alone — even if no individual statement on the label mentions heart disease or diabetes. Under 21 CFR 101.93(g)(2)(iv)(A), the product name itself is evaluated as part of the labeling context.
Lay terminology: "Helps prevent the hardening of arteries" uses lay terms, but the FDA evaluates lay and scientific terminology equally under 21 CFR 101.93(g)(2)(ii). Arteriosclerosis is a disease. Saying a product "helps prevent hardening of arteries" is a disease claim regardless of the vocabulary used.
Citing publications: If your label or website cites a study on a disease treatment — even without making the claim directly — and the citation implies treatment or prevention in context, it can constitute a disease claim under 21 CFR 101.93(g)(2)(iv)(C).
Images and symbols: Using images of diseased tissue, heart monitors, or other disease-associated imagery can tip an otherwise permissible claim into disease territory under 21 CFR 101.93(g)(2)(iv)(E).
Common Claims That Cross the Line
These claims appear regularly on supplement labels and consistently draw FDA scrutiny:
Claim | Why It's a Problem |
|---|---|
"Reduces inflammation" | Inflammation underlies specific disease states; claim implies treatment |
"Lowers blood pressure" | Hypertension is a named disease under 21 CFR 101.93(g)(1) |
"Improves insulin sensitivity" | Insulin resistance is a diabetes-adjacent condition |
"Fights cancer cells" | Explicit disease claim |
"Relieves symptoms of anxiety" | Anxiety disorders are classified diseases |
"Helps with ADHD" | Named condition = disease claim |
"Supports recovery from injury" | Injury treatment = disease territory |
"Reduces risk of Alzheimer's" | Named disease |
"Helps with menopause symptoms" | Symptoms of a natural process can still constitute disease claims if abnormal (21 CFR 101.93(g)(2)(iii)) |
The Difference Between Structure/Function and Disease Claims in Practice
The same physiological outcome can often be expressed as either a permissible structure/function claim or a prohibited disease claim, depending on how it's framed.
Permitted: "Supports healthy blood pressure already within the normal range"
Prohibited: "Lowers high blood pressure"
Permitted: "Supports healthy joint function"
Prohibited: "Relieves arthritis pain"
Permitted: "Promotes mental clarity and focus"
Prohibited: "Treats ADHD"
Permitted: "Supports healthy immune function"
Prohibited: "Prevents colds and flu"
The distinction in each pair is whether the claim assumes a diseased baseline. Structure/function claims speak to maintaining or supporting normal function. Disease claims imply correcting a dysfunction.
The "characteristic signs or symptoms" trap
One of the most frequently misunderstood criteria is 21 CFR 101.93(g)(2)(ii): claims that reference the characteristic signs or symptoms of a disease — using lay terminology — constitute disease claims.
This is why "relieves joint pain" is a disease claim. Pain is a characteristic symptom of arthritis (a disease), and claiming to relieve it implies treatment of that disease — even though the word "arthritis" never appears.
What Happens When You Make a Disease Claim
A supplement label bearing a disease claim is misbranded as a drug under 21 U.S.C. 331. The consequences:
FDA warning letter — public, searchable, cited by retailers and investors
Injunction — court order requiring you to stop selling the product
Product seizure — FDA can physically seize product in the market
Import alert — if you manufacture overseas, product can be detained at the border
Retail delistment — retailers who see warning letters routinely remove products from shelves
The FDA also has a public warning letter database. A warning letter about your brand doesn't just create legal exposure — it surfaces in investor diligence, buyer reviews, and competitive research.
Review your labels before the FDA does
Disease claim violations are one of the most common findings in Truli's label scans — and they're almost always unintentional. Brands write copy that sounds compelling, nobody checks it against 21 CFR 101.93(g), and it ships. Truli identifies disease-adjacent language across your label, website, and social content, and tells you specifically which regulatory criteria the claim implicates — before enforcement does.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
